ImpediMed Limited Share Price
Stocks
IPD
AU000000IPD8
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
Australian S.E.
05:10:11 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 0.004000 AUD | -11.11% |
|
-.--% | -88.24% |
| 10-29 | ImpediMed Limited, Q1 2027 Earnings Call, Oct 30, 2026 | |
| 10-27 | Impedimed Announces Appointment of Nicole L. Stout as Chief Clinical Innovation Officer | CI |
| Market Cap | 14.65M 10.31M 9.23M 8.49M 7.69M 14.38M 979M 101M 40.65M 515M 38.68M 37.86M 1.62B | P/E 2027 * |
-1.29x | P/E 2028 * | -2x |
|---|---|---|---|---|---|
| Enterprise Value | 20.36M 14.32M 12.83M 11.8M 10.69M 19.99M 1.36B 141M 56.49M 715M 53.76M 52.61M 2.26B | EV / Sales 2027 * |
0.99x | EV / Sales 2028 * | 0.8x |
| Free-Float |
84.63% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| IPD | Delayed | |
OTC Markets
| IPDQF | Delayed | |
|
Deutsche Boerse AG
| R1J | Delayed |
Last Transcript: ImpediMed Limited
| 01-30 | Bell Potter rates IPD as Speculative Buy | AQ |
| 01-30 | Morgans rates IPD as Speculative Buy | AQ |
| 10/02/25 | ImpediMed Secures $15m Growth Capital Funding | AQ |
| 05/07/24 | Morgans rates IPD as Add | AQ |
| 01/05/24 | Ord Minnett rates IPD as Speculaitve Buy | AQ |
| 1 day | -11.11% | ||
| 1 month | -20.00% | ||
| 3 months | -11.11% | ||
| 6 months | -71.43% | ||
| Current year | -88.24% |
| 1 week | 0 |  | 0 |
| 1 month | 0 | | 0.01 |
| Current year | 0 | | 0.04 |
| 1 year | 0 | | 0.04 |
| 3 years | 0 | | 0.16 |
| 5 years | 0 | | 0.24 |
| 10 years | 0 | | 1.58 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Anderson
CEO | Chief Executive Officer | - | 06/05/2026 |
McGregor Grant
DFI | Director of Finance/CFO | - | 19/11/2023 |
Steven Chen
CTO | Chief Tech/Sci/R&D Officer | - | 25/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
McGregor Grant
CHM | Chairman | - | - |
| Chairman | - | 25/02/2024 | |
Janelle Delaney
BRD | Director/Board Member | - | 27/09/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/01/26 | Buy | Chairman | 146,408 | 0.0072% | ||
| 16/01/26 | Buy | Director | 100,563 | 0.0049% | ||
| 16/01/26 | Buy | Director | 100,563 | 0.0049% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -11.11% | -.--% | -89.47% | -96.52% | 10.31M | |
| -1.72% | +3.44% | +22.84% | +56.71% | 258B | |
| -2.00% | +0.75% | +7.82% | +20.94% | 163B | |
| -3.73% | -4.48% | -19.14% | +64.75% | 150B | |
| -1.66% | -8.12% | -58.32% | -17.99% | 60.84B | |
| -.--% | +2.46% | -11.69% | -7.41% | 53.31B | |
| -2.57% | +3.30% | +11.59% | +44.40% | 53.03B | |
| +0.84% | -3.12% | +7.47% | +62.40% | 50.67B | |
| -3.47% | +1.04% | +19.48% | +69.17% | 49.3B | |
| -3.61% | +1.99% | +32.36% | +93.99% | 45.46B | |
| Average | -2.90% | -0.27% | -7.71% | +29.04% | 88.4B | |
| Weighted average by Cap. | -2.10% | +0.15% | +4.03% | +44.65% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 20.56M 14.46M 12.95M 11.91M 10.79M 20.18M 1.37B 142M 57.03M 722M 54.27M 53.12M 2.28B | 27.58M 19.4M 17.38M 15.98M 14.48M 27.07M 1.84B 191M 76.52M 969M 72.82M 71.27M 3.06B |
| Net income | -12.84M -9.03M -8.09M -7.44M -6.74M -12.6M -858M -88.73M -35.62M -451M -33.89M -33.17M -1.42B | -6.26M -4.41M -3.95M -3.63M -3.29M -6.15M -418M -43.28M -17.38M -220M -16.53M -16.18M -694M |
| Net Debt | 5.71M 4.02M 3.6M 3.31M 3M 5.6M 381M 39.46M 15.84M 201M 15.08M 14.76M 633M | 7.39M 5.2M 4.66M 4.28M 3.88M 7.26M 494M 51.1M 20.51M 260M 19.52M 19.1M 819M |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | A$0.004000 | -11.11% | 6,077,819 |
| 29/10/26 | A$0.004500 | +12.50% | 367,485 |
| 28/10/26 | A$0.004000 | -.--% | 1,003,785 |
| 27/10/26 | A$0.004000 | -11.11% | 15,425,609 |
| 26/10/26 | A$0.004500 | +12.50% | 920,000 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IPD Stock
Select your edition
All financial news and data tailored to specific country editions
